Home > Publications database > MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. > print

001     170397
005     20240229133712.0
024 7 _ |a 10.1038/s41467-021-25325-9
|2 doi
024 7 _ |a pmid:34417456
|2 pmid
024 7 _ |a altmetric:112092692
|2 altmetric
037 _ _ |a DKFZ-2021-01906
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Kalogirou, C.
|b 0
245 _ _ |a MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer.
260 _ _ |a [London]
|c 2021
|b Nature Publishing Group UK
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1629960610_15962
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:A410#
520 _ _ |a Prostate cancer (PCa) shows strong dependence on the androgen receptor (AR) pathway. Here, we show that squalene epoxidase (SQLE), an enzyme of the cholesterol biosynthesis pathway, is overexpressed in advanced PCa and its expression correlates with poor survival. SQLE expression is controlled by micro-RNA 205 (miR-205), which is significantly downregulated in advanced PCa. Restoration of miR-205 expression or competitive inhibition of SQLE led to inhibition of de novo cholesterol biosynthesis. Furthermore, SQLE was essential for proliferation of AR-positive PCa cell lines, including abiraterone or enzalutamide resistant derivatives, and blocked transactivation of the AR pathway. Inhibition of SQLE with the FDA approved antifungal drug terbinafine also efficiently blocked orthotopic tumour growth in mice. Finally, terbinafine reduced levels of prostate specific antigen (PSA) in three out of four late-stage PCa patients. These results highlight SQLE as a therapeutic target for the treatment of advanced PCa.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
700 1 _ |a Linxweiler, J.
|b 1
700 1 _ |a Schmucker, P.
|0 0000-0002-3487-0560
|b 2
700 1 _ |a Snaebjornsson, M. T.
|0 P:(DE-He78)7b7131e0870c28d432e48873d295460f
|b 3
|u dkfz
700 1 _ |a Schmitz, W.
|0 0000-0003-0485-7303
|b 4
700 1 _ |a Wach, S.
|b 5
700 1 _ |a Krebs, M.
|b 6
700 1 _ |a Hartmann, E.
|b 7
700 1 _ |a Puhr, M.
|b 8
700 1 _ |a Müller, A.
|b 9
700 1 _ |a Spahn, M.
|b 10
700 1 _ |a Seitz, A. K.
|b 11
700 1 _ |a Frank, T.
|b 12
700 1 _ |a Marouf, H.
|b 13
700 1 _ |a Büchel, G.
|0 0000-0001-7070-7341
|b 14
700 1 _ |a Eckstein, M.
|b 15
700 1 _ |a Kübler, H.
|b 16
700 1 _ |a Eilers, M.
|0 0000-0002-0376-6533
|b 17
700 1 _ |a Saar, M.
|b 18
700 1 _ |a Junker, K.
|b 19
700 1 _ |a Röhrig, F.
|b 20
700 1 _ |a Kneitz, B.
|b 21
700 1 _ |a Rosenfeldt, M. T.
|0 0000-0001-7650-8458
|b 22
700 1 _ |a Schulze, Almut
|0 P:(DE-He78)94ae391f53fb9285e1b68f9930615af1
|b 23
|e Last author
|u dkfz
773 _ _ |a 10.1038/s41467-021-25325-9
|g Vol. 12, no. 1, p. 5066
|0 PERI:(DE-600)2553671-0
|n 1
|p 5066
|t Nature Communications
|v 12
|y 2021
|x 2041-1723
909 C O |o oai:inrepo02.dkfz.de:170397
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)7b7131e0870c28d432e48873d295460f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-He78)94ae391f53fb9285e1b68f9930615af1
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT COMMUN : 2019
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-02
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2021-02-02
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-02
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b NAT COMMUN : 2019
|d 2021-02-02
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-02
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-02
920 1 _ |0 I:(DE-He78)A410-20160331
|k A410
|l Tumor Metabolismus und Microenvironment
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A410-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21